A 91-year-old male patient with chronic obstructive pulmonary disease in the intensive care unit was issued a red blood cell unit. Shortly after issuance, the transfusion failed because of an occlusion in the bedside leukocyte reduction filter. A small clot was observed at the spike portion of the returned filter, but the transfusion failure persisted despite replacement of the filter. On the bedside inspection, a large, irregularly shaped dark clot, approximately 2×2.5 cm in size, was observed within the blood bag, obstructing the filter spike and preventing blood flow. The unit was retrieved and classified as unsuitable for transfusion, and the supplying blood center was notified. A replacement red blood cell unit was then issued. This case highlights the importance of careful visual inspections and prompt management of abnormal blood components to ensure transfusion safety.

A 64-year-old male patient diagnosed with B-cell lymphoma required regular platelet transfusions due to persistent thrombocytopenia. Over time, he developed severe transfusion-related allergic reactions, including anaphylaxis, necessitating the use of washed apheresis platelets (W-APLT). However, as the designated blood center was unable to produce W-APLT, the issue was resolved by collaborating with a neighboring blood center to source the product.Key strategies included verifying the patient’s history of transfusion-related anaphylaxis, coordinating the production schedule of blood products, and implementing administrative procedures such as pre-scheduled ambulance transport on the day of transfusion. These measures ensured the timely supply of W-APLT while minimizing the risk of product wastage. As a result, the patient successfully received multiple W-APLT transfusions without further allergic reactions. This case serves as a model for overcoming infrastructure limitations in W-APLT supply through hospital-blood center collaboration, to provide timely and safe blood products to patients at risk of severe transfusion-related allergic reactions and anaphylaxis.

A 64-year-old male patient diagnosed with B-cell lymphoma required regular platelet transfusions due to persistent thrombocytopenia. Over time, he developed severe transfusion-related allergic reactions, including anaphylaxis, necessitating the use of washed apheresis platelets (W-APLT). However, as the designated blood center was unable to produce W-APLT, the issue was resolved by collaborating with a neighboring blood center to source the product.Key strategies included verifying the patient’s history of transfusion-related anaphylaxis, coordinating the production schedule of blood products, and implementing administrative procedures such as pre-scheduled ambulance transport on the day of transfusion. These measures ensured the timely supply of W-APLT while minimizing the risk of product wastage. As a result, the patient successfully received multiple W-APLT transfusions without further allergic reactions. This case serves as a model for overcoming infrastructure limitations in W-APLT supply through hospital-blood center collaboration, to provide timely and safe blood products to patients at risk of severe transfusion-related allergic reactions and anaphylaxis.

A 64-year-old male patient diagnosed with B-cell lymphoma required regular platelet transfusions due to persistent thrombocytopenia. Over time, he developed severe transfusion-related allergic reactions, including anaphylaxis, necessitating the use of washed apheresis platelets (W-APLT). However, as the designated blood center was unable to produce W-APLT, the issue was resolved by collaborating with a neighboring blood center to source the product.Key strategies included verifying the patient’s history of transfusion-related anaphylaxis, coordinating the production schedule of blood products, and implementing administrative procedures such as pre-scheduled ambulance transport on the day of transfusion. These measures ensured the timely supply of W-APLT while minimizing the risk of product wastage. As a result, the patient successfully received multiple W-APLT transfusions without further allergic reactions. This case serves as a model for overcoming infrastructure limitations in W-APLT supply through hospital-blood center collaboration, to provide timely and safe blood products to patients at risk of severe transfusion-related allergic reactions and anaphylaxis.

A 64-year-old male patient diagnosed with B-cell lymphoma required regular platelet transfusions due to persistent thrombocytopenia. Over time, he developed severe transfusion-related allergic reactions, including anaphylaxis, necessitating the use of washed apheresis platelets (W-APLT). However, as the designated blood center was unable to produce W-APLT, the issue was resolved by collaborating with a neighboring blood center to source the product.Key strategies included verifying the patient’s history of transfusion-related anaphylaxis, coordinating the production schedule of blood products, and implementing administrative procedures such as pre-scheduled ambulance transport on the day of transfusion. These measures ensured the timely supply of W-APLT while minimizing the risk of product wastage. As a result, the patient successfully received multiple W-APLT transfusions without further allergic reactions. This case serves as a model for overcoming infrastructure limitations in W-APLT supply through hospital-blood center collaboration, to provide timely and safe blood products to patients at risk of severe transfusion-related allergic reactions and anaphylaxis.

Many medical institutions have adopted a massive transfusion protocol (MTP) for the effective management of hemorrhagic shock. However, in medical institutions where severe trauma patients are infrequently admitted, the use of MTP is rare, potentially leading to deficiencies in staff proficiency and confidence when responding to severe hemorrhage events. This study introduced simulation training to improve staff skills and confidence and assess the current state of the MTP. Healthcare professionals, including physicians, nurses, medical technologist, and support staff from emergency medical center and blood bank, participated in two simulation training sessions.The Red Blood Cell (RBC) turnaround time (TAT) failed to meet the 5-minute target in both sessions, with recorded times of 10 minutes and 9 minutes, respectively. The fresh frozen plasma (FFP) TAT exceeded the 20-minute target in the first session but achieved the goal with a time of 19 minutes in the second session. Consequently, the RBC TAT target was adjusted to a more realistic 10 minutes. Operational changes, such as installing a blood product refrigerator in the emergency department and prioritizing MTP activities, were suggested to further reduce TAT. Simulation-based training can improve compliance with MTP procedures and increase staff confidence. For institutions where MTP activation is infrequent, regular simulation training and the dissemination of educational materials are crucial to ensuring a prompt and accurate response in actual severe hemorrhage events.